Infusion not sold yet - good news because cash in the bank makes ahz less desperate, which should hopefully fetch a better price.
Infusion is currently generating cash, but is a distraction from the main event and is a barrier to consolidating the bulk of operations/management to the US. Better to invest the capital into expanding adapt into China - much larger market - and accelerating TAVR.
Forecasting profitability and a huge sales increase was a blunder, which cost the share price dearly. Dilution has been bad, but we have money in the bank and Star Bright to help us push into China.
Completely understand those that have decided to throw in the towel, but (this time
) I think the share price has definitely bottomed out. Upcoming quarterly should push us higher if US 3D sales prove solid and TGA/EU approval presents further upside opportunity (as does selling infusion at a good price)
- Forums
- ASX - By Stock
- AVR
- AHZ Technical Analysis
AHZ Technical Analysis, page-168
-
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$15.40 |
Change
0.310(2.05%) |
Mkt cap ! $325.5M |
Open | High | Low | Value | Volume |
$15.57 | $15.84 | $15.15 | $452.1K | 29.37K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | $15.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.40 | 2886 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 15.150 |
2 | 273 | 15.090 |
1 | 26 | 15.020 |
1 | 15 | 15.010 |
2 | 832 | 15.000 |
Price($) | Vol. | No. |
---|---|---|
15.400 | 2886 | 1 |
15.580 | 500 | 1 |
15.660 | 1652 | 1 |
15.940 | 554 | 1 |
15.950 | 848 | 2 |
Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |